<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Oncol</journal-id><journal-id journal-id-type="publisher-id">CO</journal-id><journal-title>Current Oncology</journal-title><issn pub-type="ppub">1198-0052</issn><publisher><publisher-name>Multimed Inc.</publisher-name> <publisher-loc>66 Martin St. Milton, ON, Canada L9T 2R2</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17576461</article-id><article-id pub-id-type="pmc">1891190</article-id><article-id pub-id-type="publisher-id">co14_1p027</article-id><article-categories><subj-group subj-group-type="heading"><subject>Practice Guideline Series</subject></subj-group></article-categories><title-group><article-title>Temozolomide for the treatment of metastatic melanoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Quirbt</surname><given-names>I.</given-names></name><degrees>MD</degrees><xref rid="af1-co14_1p027" ref-type="aff">*</xref><xref rid="af2-co14_1p027" ref-type="aff">†</xref></contrib><contrib contrib-type="author"><name><surname>Verma</surname><given-names>S.</given-names></name><degrees>MD</degrees><xref rid="af1-co14_1p027" ref-type="aff">*</xref><xref rid="af3-co14_1p027" ref-type="aff">‡</xref><xref ref-type="corresp" rid="c1-co14_1p027"></xref></contrib><contrib contrib-type="author"><name><surname>Petrella</surname><given-names>T.</given-names></name><degrees>MD</degrees><xref rid="af1-co14_1p027" ref-type="aff">*</xref><xref rid="af4-co14_1p027" ref-type="aff">§</xref></contrib><contrib contrib-type="author"><name><surname>Bak</surname><given-names>K.</given-names></name><degrees>BA</degrees><xref rid="af1-co14_1p027" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name><surname>Charette</surname><given-names>M.</given-names></name><degrees>BSc</degrees><xref rid="af1-co14_1p027" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><collab>the members of the Melanoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care</collab><xref rid="af5-co14_1p027" ref-type="aff">||</xref></contrib></contrib-group><aff id="af1-co14_1p027"><label>*</label>Cancer Care Ontario Program in Evidence-Based Care, McMaster University, Hamilton, Ontario</aff><aff id="af2-co14_1p027"><label>†</label> Princess Margaret Hospital, Toronto, Ontario.</aff><aff id="af3-co14_1p027"><label>‡</label> The Ottawa Hospital, Ottawa, Ontario.</aff><aff id="af4-co14_1p027"><label>§</label> Sunnybrook Regional Cancer Center, Toronto, Ontario</aff><aff id="af5-co14_1p027"><label>||</label> Please see the Web site of Cancer Care Ontario’s Program in Evidence-Based Care (<ext-link ext-link-type="uri" xlink:href="www.cancercare.on.ca/access_PEBC.htm">www.cancercare.on.ca/access_PEBC.htm</ext-link>) for a complete list of current Melanoma Disease Site Group members.</aff><author-notes><corresp id="c1-co14_1p027"><bold><italic>Correspondence to:</italic></bold> Shailendra Verma, Co-chair, Melanoma Disease Site Group, Cancer Care Ontario’s Program in Evidence-Based Care, c/o Manya Charette, Courthouse T-27 Building, 3rd Floor, McMaster University, 1280 Main Street West, Hamilton, Ontario L8S 4L8 (Courier to: 50 Main Street East, 3rd floor, Hamilton Ontario L8N 1E9). <bold><italic>E-mail:</italic></bold><email>charet@mcmaster.ca</email></corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>2007</year></pub-date><volume>14</volume><issue>1</issue><fpage>27</fpage><lpage>33</lpage><copyright-statement>2007 Multimed Inc.</copyright-statement><copyright-year>2007</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license><abstract><sec><title><offsets xml_i="4108" xml_f="4117" txt_i="11" txt_f="20">Questions</offsets></title><p><offsets xml_i="4128" xml_f="4228" txt_i="21" txt_f="121">What is the role of single-agent temozolomide in the treatment of patients with metastatic melanoma?</offsets></p><p><offsets xml_i="4235" xml_f="4398" txt_i="122" txt_f="285">In comparison with single-agent temozolomide, does the addition of interferon-α to temozolomide improve disease-free survival, overall survival, or response rates?</offsets></p><p><offsets xml_i="4405" xml_f="4567" txt_i="286" txt_f="448">In comparison with single-agent temozolomide, does the addition of thalidomide to temozolomide improve disease-free survival, overall survival, or response rates?</offsets></p></sec><sec><title><offsets xml_i="4589" xml_f="4601" txt_i="450" txt_f="462">Perspectives</offsets></title><p><offsets xml_i="4612" xml_f="4924" txt_i="463" txt_f="775">Because of its oral route of administration and its ability to cross the blood–brain barrier, temozolomide is a potentially attractive chemotherapy agent for adult patients with unresectable metastatic malignant melanoma. To provide treatment recommendations for this new agent, the Melanoma Disease Site Group (</offsets><sc><offsets xml_i="4928" xml_f="4931" txt_i="775" txt_f="778">dsg</offsets></sc><offsets xml_i="4936" xml_f="4995" txt_i="778" txt_f="837">) of Cancer Care Ontario’s Program in Evidence-Based Care (</offsets><sc><offsets xml_i="4999" xml_f="5003" txt_i="837" txt_f="841">pebc</offsets></sc><offsets xml_i="5008" xml_f="5150" txt_i="841" txt_f="983">) decided to review the available literature on single-agent temozolomide and on temozolomide in combination with interferon-α or thalidomide.</offsets></p></sec><sec><title><offsets xml_i="5172" xml_f="5180" txt_i="985" txt_f="993">Outcomes</offsets></title><p><offsets xml_i="5191" xml_f="5315" txt_i="994" txt_f="1118">Outcomes of interest included response rates, disease-free survival, overall survival, quality of life, and adverse effects.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="5356" xml_f="5367" txt_i="1120" txt_f="1131">Methodology</offsets></title><p><offsets xml_i="5378" xml_f="5444" txt_i="1132" txt_f="1198">Evidence was selected and reviewed by two members of the Melanoma </offsets><sc><offsets xml_i="5448" xml_f="5451" txt_i="1198" txt_f="1201">dsg</offsets></sc><offsets xml_i="5456" xml_f="5560" txt_i="1201" txt_f="1305"> and by methodologists. The present practice guideline report was reviewed and approved by the Melanoma </offsets><sc><offsets xml_i="5564" xml_f="5567" txt_i="1305" txt_f="1308">dsg</offsets></sc><offsets xml_i="5572" xml_f="5900" txt_i="1308" txt_f="1636">, which comprises medical and radiation oncologists, surgeons, and dermatologists. External review was obtained through a mailed survey of Ontario practitioners, the results of which were reflected in revisions to the practice guideline. Final approval of the guideline report was obtained from the Report Approval Panel of the </offsets><sc><offsets xml_i="5904" xml_f="5908" txt_i="1636" txt_f="1640">pbec</offsets></sc><offsets xml_i="5913" xml_f="5914" txt_i="1640" txt_f="1641">.</offsets></p></sec><sec><title><offsets xml_i="5936" xml_f="5954" txt_i="1643" txt_f="1661">Practice Guideline</offsets></title><p><offsets xml_i="5965" xml_f="6059" txt_i="1662" txt_f="1756">These recommendations apply to adult patients with unresectable metastatic malignant melanoma.</offsets></p><p><offsets xml_i="6066" xml_f="6124" txt_i="1757" txt_f="1815">It is reasonable to use temozolomide at a dose of 200 mg/m</offsets><sup><offsets xml_i="6129" xml_f="6130" txt_i="1815" txt_f="1816">2</offsets></sup><offsets xml_i="6136" xml_f="6260" txt_i="1816" txt_f="1940"> orally for 5 days every 4 weeks as initial systemic treatment for patients with unresectable metastatic malignant melanoma.</offsets></p><p><offsets xml_i="6267" xml_f="6426" txt_i="1941" txt_f="2100">The addition of moderate-dose interferon-α 2b has produced a significantly higher response rate than has single-agent temozolomide in a large randomized phase </offsets><sc><offsets xml_i="6430" xml_f="6433" txt_i="2100" txt_f="2103">iii</offsets></sc><offsets xml_i="6438" xml_f="6657" txt_i="2103" txt_f="2322"> study. However, overall survival was not altered, and grades 3 and 4 hematologic toxicities were higher with the combined treatment. At the present time, the addition of interferon-α to temozolomide is not recommended.</offsets></p><p><offsets xml_i="6664" xml_f="6685" txt_i="2323" txt_f="2344">One randomized phase </offsets><sc><offsets xml_i="6689" xml_f="6691" txt_i="2344" txt_f="2346">ii</offsets></sc><offsets xml_i="6696" xml_f="6723" txt_i="2346" txt_f="2373"> study and six other phase </offsets><sc><offsets xml_i="6727" xml_f="6729" txt_i="2373" txt_f="2375">ii</offsets></sc><offsets xml_i="6734" xml_f="7169" txt_i="2375" txt_f="2810"> studies showed encouraging response rates when thalidomide was combined with temozolomide. However, the doses and schedules of temozolomide in those studies differed from the conventionally prescribed doses and schedules. It is not clear whether the improved response rates were attributable to the small number of patients in the studies, the different temozolomide doses and schedules, or the addition of thalidomide. Further phase </offsets><sc><offsets xml_i="7173" xml_f="7176" txt_i="2810" txt_f="2813">iii</offsets></sc><offsets xml_i="7181" xml_f="7394" txt_i="2813" txt_f="3026"> studies are required to confirm whether a benefit is associated with the combination of temozolomide and thalidomide. Therefore, at this time, it is not recommended that thalidomide be combined with temozolomide.</offsets></p></sec><sec><title><offsets xml_i="7416" xml_f="7437" txt_i="3028" txt_f="3049">Qualifying Statements</offsets></title><p><offsets xml_i="7448" xml_f="7977" txt_i="3050" txt_f="3579">Dacarbazine is the only chemotherapy drug currently approved for the treatment of metastatic malignant melanoma. In large randomized trials, response rates with dacarbazine ranged from 6% to 15%. Almost all responses were partial, with a median response duration of only 7–8 months. Given these disappointing overall results, the consensus among most physicians who are treating patients with metastatic malignant melanoma is that recommending more convenient treatment or experimental treatment to these patients is appropriate.</offsets></p><p><offsets xml_i="7984" xml_f="8154" txt_i="3580" txt_f="3750">Because of oral dosing, temozolomide is a reasonable choice, particularly for patients who would have difficulty traveling to cancer centres for intravenous chemotherapy.</offsets></p><p><offsets xml_i="8161" xml_f="8251" txt_i="3751" txt_f="3841">Temozolomide has demonstrated efficacy equal to that of dacarbazine in a randomized phase </offsets><sc><offsets xml_i="8255" xml_f="8258" txt_i="3841" txt_f="3844">iii</offsets></sc><offsets xml_i="8263" xml_f="8659" txt_i="3844" txt_f="4240"> trial. However, unlike dacarbazine, temozolomide is a convenient oral treatment that penetrates the blood–brain barrier and that has shown activity against brain metastases. Although surgery is the preferred treatment modality for patients with solitary brain metastases from melanoma, temozolomide is the preferred chemotherapy for patients with brain metastases who require systemic treatment.</offsets></p></sec></abstract><kwd-group><kwd>Melanoma</kwd><kwd>temozolomide</kwd><kwd>temodal</kwd><kwd>guideline report</kwd></kwd-group></article-meta></front><body><sec><title><offsets xml_i="8831" xml_f="8843" txt_i="4249" txt_f="4261">1. QUESTIONS</offsets></title><p><offsets xml_i="8854" xml_f="8954" txt_i="4262" txt_f="4362">What is the role of single-agent temozolomide in the treatment of patients with metastatic melanoma?</offsets></p><p><offsets xml_i="8961" xml_f="9124" txt_i="4363" txt_f="4526">In comparison with single-agent temozolomide, does the addition of interferon-α to temozolomide improve disease-free survival, overall survival, or response rates?</offsets></p><p><offsets xml_i="9131" xml_f="9293" txt_i="4527" txt_f="4689">In comparison with single-agent temozolomide, does the addition of thalidomide to temozolomide improve disease-free survival, overall survival, or response rates?</offsets></p><p><offsets xml_i="9300" xml_f="9424" txt_i="4690" txt_f="4814">Outcomes of interest included response rates, disease-free survival, overall survival, quality of life, and adverse effects.</offsets></p></sec><sec><title><offsets xml_i="9446" xml_f="9478" txt_i="4816" txt_f="4848">2. CHOICE OF TOPIC AND RATIONALE</offsets></title><p><offsets xml_i="9489" xml_f="9678" txt_i="4849" txt_f="5038">It has been estimated that, during 2005, 4400 new cases of melanoma will have been diagnosed in Canada and that, of 880 estimated deaths from the disease, 420 will have occurred in Ontario </offsets><xref ref-type="bibr" rid="b1-co14_1p027"><offsets xml_i="9720" xml_f="9721" txt_i="5038" txt_f="5039">1</offsets></xref><offsets xml_i="9728" xml_f="10070" txt_i="5039" txt_f="5381">. Primary surgical treatment cures most patients diagnosed with early-stage malignant melanoma. However, people with deeply invasive melanoma have a high probability of developing distant metastases. Adjuvant therapy has been found to be partially effective, but the currently available systemic treatments have yielded disappointing results.</offsets></p><p><offsets xml_i="10077" xml_f="10526" txt_i="5382" txt_f="5831">Recently, temozolomide has emerged as a promising novel chemotherapy agent in malignant melanoma. Temozolomide acts through the same mechanism as dacarbazine; however, unlike dacarbazine, temozolomide has excellent oral bioavailability and possesses the ability to cross the blood–brain barrier. These added benefits suggest that temozolomide may play a role in treating patients with metastases to the brain, a frequent metastatic site in melanoma.</offsets></p><p><offsets xml_i="10533" xml_f="10623" txt_i="5832" txt_f="5922">To provide treatment recommendations for this new agent, the Melanoma Disease Site Group (</offsets><sc><offsets xml_i="10627" xml_f="10630" txt_i="5922" txt_f="5925">dsg</offsets></sc><offsets xml_i="10635" xml_f="10777" txt_i="5925" txt_f="6067">) decided to review the available literature on single-agent temozolomide and on temozolomide in combination with interferon-α or thalidomide.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="10818" xml_f="10828" txt_i="6069" txt_f="6079">3. METHODS</offsets></title><sec><title><offsets xml_i="10848" xml_f="10873" txt_i="6080" txt_f="6105">3.1 Guideline Development</offsets></title><p><offsets xml_i="10884" xml_f="10986" txt_i="6106" txt_f="6208">This practice guideline report was developed by Cancer Care Ontario’s Program in Evidence-Based Care (</offsets><sc><offsets xml_i="10990" xml_f="10994" txt_i="6208" txt_f="6212">pebc</offsets></sc><offsets xml_i="10999" xml_f="11064" txt_i="6212" txt_f="6277">) using the methods of the practice guidelines development cycle </offsets><xref ref-type="bibr" rid="b2-co14_1p027"><offsets xml_i="11106" xml_f="11107" txt_i="6277" txt_f="6278">2</offsets></xref><offsets xml_i="11114" xml_f="11182" txt_i="6278" txt_f="6346">. Evidence was selected and reviewed by two members of the Melanoma </offsets><sc><offsets xml_i="11186" xml_f="11189" txt_i="6346" txt_f="6349">dsg</offsets></sc><offsets xml_i="11194" xml_f="11242" txt_i="6349" txt_f="6397"> and by methodologists. Members of the Melanoma </offsets><sc><offsets xml_i="11246" xml_f="11249" txt_i="6397" txt_f="6400">dsg</offsets></sc><offsets xml_i="11254" xml_f="11308" txt_i="6400" txt_f="6454"> disclosed potential conflict of interest information.</offsets></p><p><offsets xml_i="11315" xml_f="11863" txt_i="6455" txt_f="7003">The practice guideline is a convenient and up-to-date source of the best available evidence on single-agent temozolomide or temozolomide in combination with interferon-α or thalidomide in the treatment of metastatic melanoma. The present report was developed through systematic reviews, evidence synthesis, and input from practitioners in Ontario. It is a companion piece to a systematic review which is currently under consideration for publication elsewhere. Both documents are intended to promote evidence-based practice in Ontario, Canada. The </offsets><sc><offsets xml_i="11867" xml_f="11871" txt_i="7003" txt_f="7007">pebc</offsets></sc><offsets xml_i="11876" xml_f="11981" txt_i="7007" txt_f="7112"> is editorially independent of Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.</offsets></p></sec><sec sec-type="background"><title><offsets xml_i="12025" xml_f="12055" txt_i="7114" txt_f="7144">3.2 Literature Search Strategy</offsets></title><p><offsets xml_i="12066" xml_f="12070" txt_i="7145" txt_f="7149">The </offsets><sc><offsets xml_i="12074" xml_f="12081" txt_i="7149" txt_f="7156">medline</offsets></sc><offsets xml_i="12086" xml_f="12122" txt_i="7156" txt_f="7192"> [1966 to September (week 3) 2005], </offsets><sc><offsets xml_i="12126" xml_f="12132" txt_i="7192" txt_f="7198">embase</offsets></sc><offsets xml_i="12137" xml_f="12314" txt_i="7198" txt_f="7375"> (1980 to week 40, 2005), and the Cochrane Library (Issue 3, 2005) were systematically searched using a combination of the following terms: “melanoma” [Medical Subject Heading, </offsets><italic><offsets xml_i="12322" xml_f="12337" txt_i="7375" txt_f="7390">Excerpta Medica</offsets></italic><offsets xml_i="12346" xml_f="12353" txt_i="7390" txt_f="7397"> Tree (</offsets><sc><offsets xml_i="12357" xml_f="12363" txt_i="7397" txt_f="7403">emtree</offsets></sc><offsets xml_i="12368" xml_f="12408" txt_i="7403" txt_f="7443">) term, and text word], “temozolomide” (</offsets><sc><offsets xml_i="12412" xml_f="12418" txt_i="7443" txt_f="7449">emtree</offsets></sc><offsets xml_i="12423" xml_f="12711" txt_i="7449" txt_f="7737"> term and text word), “temodal” (text word), and “temodar” (text word). Those terms were then combined with the search terms for the following publication types and study designs: practice guidelines, systematic reviews, meta-analyses, randomized controlled trials, and controlled trials.</offsets></p><p><offsets xml_i="12718" xml_f="13093" txt_i="7738" txt_f="8113">In addition, the proceedings of the 1997–2005 annual meetings of the American Society of Clinical Oncology were searched for reports of newly completed trials. Relevant articles and abstracts were selected and reviewed by two reviewers, and the reference lists from those sources were searched for additional trials, as were the reference lists from relevant review articles.</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="13140" xml_f="13150" txt_i="8116" txt_f="8126">4. RESULTS</offsets></title><sec sec-type="background"><title><offsets xml_i="13192" xml_f="13213" txt_i="8127" txt_f="8148">4.1 Literature Search</offsets></title><p><offsets xml_i="13224" xml_f="13278" txt_i="8149" txt_f="8203">The literature search identified two randomized phase </offsets><sc><offsets xml_i="13282" xml_f="13285" txt_i="8203" txt_f="8206">iii</offsets></sc><offsets xml_i="13290" xml_f="13325" txt_i="8206" txt_f="8241"> trials and three randomized phase </offsets><sc><offsets xml_i="13329" xml_f="13331" txt_i="8241" txt_f="8243">ii</offsets></sc><offsets xml_i="13336" xml_f="13496" txt_i="8243" txt_f="8403"> trials of single-agent temozolomide compared with either single-agent intravenous dacarbazine or combinations of temozolomide with cisplatin, interferon-α 2b (</offsets><sc><offsets xml_i="13500" xml_f="13503" txt_i="8403" txt_f="8406">ifn</offsets></sc><offsets xml_i="13508" xml_f="13546" txt_i="8406" txt_f="8444">), or thalidomide. Another nine phase </offsets><sc><offsets xml_i="13550" xml_f="13552" txt_i="8444" txt_f="8446">ii</offsets></sc><offsets xml_i="13557" xml_f="13568" txt_i="8446" txt_f="8457"> and phase </offsets><sc><offsets xml_i="13572" xml_f="13573" txt_i="8457" txt_f="8458">i</offsets></sc><offsets xml_i="13578" xml_f="13853" txt_i="8458" txt_f="8733"> trials investigating single-agent temozolomide, six trials investigating temozolomide plus interferon-α, and six trials investigating temozolomide plus thalidomide were reviewed. Sixteen of the trials were published as full reports; ten were available in abstract form only.</offsets></p></sec><sec><title><offsets xml_i="13875" xml_f="13887" txt_i="8735" txt_f="8747">4.2 Outcomes</offsets></title><sec><title><offsets xml_i="13907" xml_f="13940" txt_i="8748" txt_f="8781">4.2.1 Randomized Phase III Trials</offsets></title><p><offsets xml_i="13951" xml_f="13991" txt_i="8782" txt_f="8822">Evidence from the two randomized trials </offsets><xref ref-type="bibr" rid="b3-co14_1p027"><offsets xml_i="14033" xml_f="14034" txt_i="8822" txt_f="8823">3</offsets></xref><offsets xml_i="14041" xml_f="14042" txt_i="8823" txt_f="8824">,</offsets><xref ref-type="bibr" rid="b4-co14_1p027"><offsets xml_i="14084" xml_f="14085" txt_i="8824" txt_f="8825">4</offsets></xref><offsets xml_i="14092" xml_f="14240" txt_i="8825" txt_f="8973"> shows that it is reasonable to use temozolomide as initial treatment for patients with unresectable metastatic malignant melanoma. The first trial </offsets><xref ref-type="bibr" rid="b3-co14_1p027"><offsets xml_i="14282" xml_f="14283" txt_i="8973" txt_f="8974">3</offsets></xref><offsets xml_i="14290" xml_f="14402" txt_i="8974" txt_f="9086"> compared single-agent temozolomide with single-agent intravenous dacarbazine in 305 patients. The second trial </offsets><xref ref-type="bibr" rid="b4-co14_1p027"><offsets xml_i="14444" xml_f="14445" txt_i="9086" txt_f="9087">4</offsets></xref><offsets xml_i="14452" xml_f="14520" txt_i="9087" txt_f="9155"> compared single-agent temozolomide with temozolomide combined with </offsets><sc><offsets xml_i="14524" xml_f="14527" txt_i="9155" txt_f="9158">ifn</offsets></sc><offsets xml_i="14532" xml_f="14549" txt_i="9158" txt_f="9175"> in 294 patients.</offsets></p><p><offsets xml_i="14556" xml_f="14599" txt_i="9176" txt_f="9219">Results from the first trial, by Middleton </offsets><italic><offsets xml_i="14607" xml_f="14614" txt_i="9219" txt_f="9226">et al.,</offsets></italic><offsets xml_i="14623" xml_f="14765" txt_i="9226" txt_f="9368"> demonstrated that progression-free survival was significantly prolonged in patients treated with temozolomide, with a reported hazard ratio (</offsets><sc><offsets xml_i="14769" xml_f="14771" txt_i="9368" txt_f="9370">hr</offsets></sc><offsets xml_i="14776" xml_f="14812" txt_i="9370" txt_f="9406">) of 1.37 [95% confidence interval (</offsets><sc><offsets xml_i="14816" xml_f="14818" txt_i="9406" txt_f="9408">ci</offsets></sc><offsets xml_i="14823" xml_f="14840" txt_i="9408" txt_f="9425">): 1.07 to 1.75; </offsets><italic><offsets xml_i="14848" xml_f="14849" txt_i="9425" txt_f="9426">p</offsets></italic><offsets xml_i="14858" xml_f="15330" txt_i="9426" txt_f="9898"> = 0.012]. Median survival for patients treated with temozolomide was 7.7 months versus 6.4 months for those treated with dacarbazine. However, the difference between the two treatment groups was not statistically significant. Of the patients in the temozolomide arm, 21 (14%) showed an objective response to treatment; of patients in the dacarbazine arm, 18 (12%) showed an objective response. Grades 3 and 4 hematologic toxicities were similar in the two treatment arms.</offsets></p><p><offsets xml_i="15337" xml_f="15346" txt_i="9899" txt_f="9908">Kaufmann </offsets><italic><offsets xml_i="15354" xml_f="15360" txt_i="9908" txt_f="9914">et al.</offsets></italic><offsets xml_i="15369" xml_f="15370" txt_i="9914" txt_f="9915"> </offsets><xref ref-type="bibr" rid="b4-co14_1p027"><offsets xml_i="15412" xml_f="15413" txt_i="9915" txt_f="9916">4</offsets></xref><offsets xml_i="15420" xml_f="15498" txt_i="9916" txt_f="9994"> reported a significantly higher response rate for temozolomide combined with </offsets><sc><offsets xml_i="15502" xml_f="15505" txt_i="9994" txt_f="9997">ifn</offsets></sc><offsets xml_i="15510" xml_f="15568" txt_i="9997" txt_f="10055"> as compared with single-agent temozolomide (24% vs. 13%; </offsets><italic><offsets xml_i="15576" xml_f="15577" txt_i="10055" txt_f="10056">p</offsets></italic><offsets xml_i="15586" xml_f="15904" txt_i="10056" txt_f="10371"> &lt; 0.036). In the combination arm, 11 patients (8%) achieved a complete response, and 22 patients (16%) showed a partial response, as compared with 3 patients (2%) and 15 patients (11%) respectively in the temozolomide group. The median overall survival was reported to be 8.4 months in the temozolomide group (95% </offsets><sc><offsets xml_i="15908" xml_f="15910" txt_i="10371" txt_f="10373">ci</offsets></sc><offsets xml_i="15915" xml_f="15971" txt_i="10373" txt_f="10429">: 7.07 to 9.72) and 9.7 months in the temozolomide plus </offsets><sc><offsets xml_i="15975" xml_f="15978" txt_i="10429" txt_f="10432">ifn</offsets></sc><offsets xml_i="15983" xml_f="15995" txt_i="10432" txt_f="10444"> group (95% </offsets><sc><offsets xml_i="15999" xml_f="16001" txt_i="10444" txt_f="10446">ci</offsets></sc><offsets xml_i="16006" xml_f="16065" txt_i="10446" txt_f="10505">: 8.26 to 11.18); no statistical significance was detected.</offsets></p></sec><sec><title><offsets xml_i="16087" xml_f="16119" txt_i="10507" txt_f="10539">4.2.2 Randomized Phase II Trials</offsets></title><p><offsets xml_i="16130" xml_f="16186" txt_i="10540" txt_f="10596">The systematic review identified three randomized phase </offsets><sc><offsets xml_i="16190" xml_f="16192" txt_i="10596" txt_f="10598">ii</offsets></sc><offsets xml_i="16197" xml_f="16205" txt_i="10598" txt_f="10606"> trials </offsets><xref ref-type="bibr" rid="b5-co14_1p027"><offsets xml_i="16247" xml_f="16248" txt_i="10606" txt_f="10607">5</offsets></xref><offsets xml_i="16255" xml_f="16256" txt_i="10607" txt_f="10608">–</offsets><xref ref-type="bibr" rid="b7-co14_1p027"><offsets xml_i="16298" xml_f="16299" txt_i="10608" txt_f="10609">7</offsets></xref><offsets xml_i="16306" xml_f="16327" txt_i="10609" txt_f="10630">. In the first trial </offsets><xref ref-type="bibr" rid="b5-co14_1p027"><offsets xml_i="16369" xml_f="16370" txt_i="10630" txt_f="10631">5</offsets></xref><offsets xml_i="16377" xml_f="16489" txt_i="10631" txt_f="10743">, 127 patients were randomized to receive temozolomide alone or in combination with cisplatin. The second trial </offsets><xref ref-type="bibr" rid="b6-co14_1p027"><offsets xml_i="16531" xml_f="16532" txt_i="10743" txt_f="10744">6</offsets></xref><offsets xml_i="16539" xml_f="16631" txt_i="10744" txt_f="10836"> randomized 181 patients to receive temozolomide alone or temozolomide combined with either </offsets><sc><offsets xml_i="16635" xml_f="16638" txt_i="10836" txt_f="10839">ifn</offsets></sc><offsets xml_i="16643" xml_f="16676" txt_i="10839" txt_f="10872"> or thalidomide. The third trial </offsets><xref ref-type="bibr" rid="b7-co14_1p027"><offsets xml_i="16718" xml_f="16719" txt_i="10872" txt_f="10873">7</offsets></xref><offsets xml_i="16726" xml_f="16797" txt_i="10873" txt_f="10944"> randomized 47 patients to a treatment combination of temozolomide and </offsets><sc><offsets xml_i="16801" xml_f="16804" txt_i="10944" txt_f="10947">ifn</offsets></sc><offsets xml_i="16809" xml_f="17008" txt_i="10947" txt_f="11146">, the latter being administered in two different dosages. None of trials detected statistically significant differences in median overall survival, time to disease progression, or objective response.</offsets></p><p><offsets xml_i="17015" xml_f="17040" txt_i="11147" txt_f="11172">Interestingly, the trial </offsets><xref ref-type="bibr" rid="b5-co14_1p027"><offsets xml_i="17082" xml_f="17083" txt_i="11172" txt_f="11173">5</offsets></xref><offsets xml_i="17090" xml_f="17618" txt_i="11173" txt_f="11701"> by Bafaloukos and colleagues detected some evidence of antitumour activity in the central nervous system, including 3 partial responses in brain metastases (1 in the temozolomide arm and 2 in the combination arm). Only 16% of patients receiving temozolomide alone and 18% of patients receiving temozolomide with cisplatin developed central nervous system metastases (median follow-up of 39.9 months and 37 months, respectively), further suggesting that treatment with temozolomide may reduce the occurrence of brain metastases.</offsets></p></sec><sec><title><offsets xml_i="17640" xml_f="17678" txt_i="11703" txt_f="11741">4.2.3 Single-Arm Phase II and I Trials</offsets></title><p><offsets xml_i="17689" xml_f="17695" txt_i="11742" txt_f="11748">Phase </offsets><sc><offsets xml_i="17699" xml_f="17701" txt_i="11748" txt_f="11750">ii</offsets></sc><offsets xml_i="17706" xml_f="17711" txt_i="11750" txt_f="11755"> and </offsets><sc><offsets xml_i="17715" xml_f="17716" txt_i="11755" txt_f="11756">i</offsets></sc><offsets xml_i="17721" xml_f="17880" txt_i="11756" txt_f="11915"> trials of single-agent temozolomide have demonstrated response rates that range from 0% to 29%, with complete responses observed in 0%–17% of patients. Phase </offsets><sc><offsets xml_i="17884" xml_f="17886" txt_i="11915" txt_f="11917">ii</offsets></sc><offsets xml_i="17891" xml_f="17896" txt_i="11917" txt_f="11922"> and </offsets><sc><offsets xml_i="17900" xml_f="17901" txt_i="11922" txt_f="11923">i</offsets></sc><offsets xml_i="17906" xml_f="17968" txt_i="11923" txt_f="11985"> trials investigating temozolomide in combination with either </offsets><sc><offsets xml_i="17972" xml_f="17975" txt_i="11985" txt_f="11988">ifn</offsets></sc><offsets xml_i="17980" xml_f="18181" txt_i="11988" txt_f="12189"> or thalidomide have reported response rates ranging from 13% to 23% and from 8% to 42% respectively. Although these response rates are encouraging, further evidence from randomized trials is required.</offsets></p></sec></sec></sec><sec><title><offsets xml_i="18215" xml_f="18239" txt_i="12193" txt_f="12217">5. DSG CONSENSUS PROCESS</offsets></title><p><offsets xml_i="18250" xml_f="18332" txt_i="12218" txt_f="12300">The practice guideline recommendations were drafted by one member of the Melanoma </offsets><sc><offsets xml_i="18336" xml_f="18339" txt_i="12300" txt_f="12303">dsg</offsets></sc><offsets xml_i="18344" xml_f="18374" txt_i="12303" txt_f="12333"> and circulated to the entire </offsets><sc><offsets xml_i="18378" xml_f="18381" txt_i="12333" txt_f="12336">dsg</offsets></sc><offsets xml_i="18386" xml_f="18458" txt_i="12336" txt_f="12408"> in February 2004 for review and consensus. The members of the Melanoma </offsets><sc><offsets xml_i="18462" xml_f="18465" txt_i="12408" txt_f="12411">dsg</offsets></sc><offsets xml_i="18470" xml_f="18594" txt_i="12411" txt_f="12535"> unanimously agreed with the draft recommendations. Before submitting the recommendations to the Report Approval Panel, the </offsets><sc><offsets xml_i="18598" xml_f="18601" txt_i="12535" txt_f="12538">dsg</offsets></sc><offsets xml_i="18606" xml_f="18846" txt_i="12538" txt_f="12778"> members discussed adding a recommendation regarding the use of temozolomide for patients with brain metastases who require systemic treatment. However, after some debate, the members decided to address that issue in a qualifying statement.</offsets></p></sec><sec><title><offsets xml_i="18868" xml_f="18892" txt_i="12780" txt_f="12804">6. PRACTITIONER FEEDBACK</offsets></title><sec sec-type="methods"><title><offsets xml_i="18931" xml_f="18942" txt_i="12805" txt_f="12816">6.1 Methods</offsets></title><p><offsets xml_i="18953" xml_f="19002" txt_i="12817" txt_f="12866">Following discussion and consensus, the Melanoma </offsets><sc><offsets xml_i="19006" xml_f="19009" txt_i="12866" txt_f="12869">dsg</offsets></sc><offsets xml_i="19014" xml_f="19622" txt_i="12869" txt_f="13477"> circulated the clinical practice guideline and systematic review to clinicians in Ontario for review. Feedback was obtained through a mailed survey of 13 practitioners in Ontario (all medical oncologists). The survey consisted of items evaluating the methods, results, and interpretive summary used to inform the draft recommendations and asking whether the draft recommendations should be approved as a practice guideline. Written comments were invited. The survey was mailed on April 23, 2004. Follow-up reminders were sent at 2 weeks (post card) and 4 weeks (complete package mailed again). The Melanoma </offsets><sc><offsets xml_i="19626" xml_f="19629" txt_i="13477" txt_f="13480">dsg</offsets></sc><offsets xml_i="19634" xml_f="19670" txt_i="13480" txt_f="13516"> reviewed the results of the survey.</offsets></p></sec><sec sec-type="results"><title><offsets xml_i="19711" xml_f="19722" txt_i="13518" txt_f="13529">6.2 Results</offsets></title><p><offsets xml_i="19733" xml_f="20174" txt_i="13530" txt_f="13971">Of the 13 practitioners surveyed, 8 (62%) responded. Responses include returned completed surveys and telephone, fax, and e-mail responses. Of the practitioners who responded, 6 indicated that the report was relevant to their clinical practice, and they completed the survey. All practitioners indicated that they agreed with the draft recommendations as stated, and most agreed that the document should be approved as a practice guideline. </offsets><xref ref-type="table" rid="tI-co14_1p027"><offsets xml_i="20217" xml_f="20224" txt_i="13971" txt_f="13978">Table I</offsets></xref><offsets xml_i="20231" xml_f="20291" txt_i="13978" txt_f="14038"> summarizes key results of the practitioner feedback survey.</offsets></p></sec><sec sec-type="conclusions"><title><offsets xml_i="20336" xml_f="20367" txt_i="14040" txt_f="14071">6.3 Summary of Written Comments</offsets></title><p><offsets xml_i="20378" xml_f="20489" txt_i="14072" txt_f="14183">Four respondents (67%) provided written comments. The main points contained in the written comments were these:</offsets></p><list list-type="bullet"><list-item><p><offsets xml_i="20532" xml_f="20601" txt_i="14184" txt_f="14253">One practitioner commented that experience with the 6-week 50–75 mg/m</offsets><sup><offsets xml_i="20606" xml_f="20607" txt_i="14253" txt_f="14254">2</offsets></sup><offsets xml_i="20613" xml_f="20687" txt_i="14254" txt_f="14328"> daily regimen is adequate to include it as a reasonable treatment option.</offsets></p></list-item><list-item><p><offsets xml_i="20717" xml_f="21100" txt_i="14329" txt_f="14712">Another practitioner commented that temozolomide is a reasonable choice of therapy only insofar as dacarbazine is reasonable. Dacarbazine should be the “default” option, and temozolomide should be used only under unusual circumstances—for example, when patients live in remote areas or lack access to intravenous treatment—and even then, monitoring the patient’s counts is important.</offsets></p></list-item><list-item><p><offsets xml_i="21130" xml_f="21364" txt_i="14713" txt_f="14947">Finally, a practitioner commented that the roles of interferon and thalidomide should be revisited in a timely manner. Also, a need exists to address the funding of temozolomide in a timely manner so that it is accessible to patients.</offsets></p></list-item></list></sec><sec><title><offsets xml_i="21405" xml_f="21430" txt_i="14949" txt_f="14974">6.4 Modifications/Actions</offsets></title><p><offsets xml_i="21441" xml_f="21454" txt_i="14975" txt_f="14988">The Melanoma </offsets><sc><offsets xml_i="21458" xml_f="21461" txt_i="14988" txt_f="14991">dsg</offsets></sc><offsets xml_i="21466" xml_f="21559" txt_i="14991" txt_f="15084"> discussed the comments resulting from practitioner feedback survey and responded as follows:</offsets></p><list list-type="bullet"><list-item><p><offsets xml_i="21602" xml_f="21648" txt_i="15085" txt_f="15131">Although experience with the 6-week 50–75 mg/m</offsets><sup><offsets xml_i="21653" xml_f="21654" txt_i="15131" txt_f="15132">2</offsets></sup><offsets xml_i="21660" xml_f="21792" txt_i="15132" txt_f="15264"> daily regimen is growing, the evidence is currently insufficient to endorse or adopt this treatment regimen in metastatic melanoma.</offsets></p></list-item><list-item><p><offsets xml_i="21822" xml_f="22193" txt_i="15265" txt_f="15636">Dacarbazine and temozolomide may both be considered reasonable therapeutic choices in patients. There is no reason to choose one over the other insofar as outcomes (overall survival, disease-free survival) are concerned. Patient preference and factors such as intravenous access, geographic location, and access to treatment facilities should be taken into consideration.</offsets></p></list-item><list-item><p><offsets xml_i="22223" xml_f="22320" txt_i="15637" txt_f="15734">As previously acknowledged in this document, the amount of high-quality evidence on the roles of </offsets><sc><offsets xml_i="22324" xml_f="22327" txt_i="15734" txt_f="15737">ifn</offsets></sc><offsets xml_i="22332" xml_f="22418" txt_i="15737" txt_f="15823"> and thalidomide in combination with temozolomide is limited. To date, only one small </offsets><sc><offsets xml_i="22422" xml_f="22425" txt_i="15823" txt_f="15826">rct</offsets></sc><offsets xml_i="22430" xml_f="22482" txt_i="15826" txt_f="15878"> has shown that the combination of temozolomide and </offsets><sc><offsets xml_i="22486" xml_f="22489" txt_i="15878" txt_f="15881">ifn</offsets></sc><offsets xml_i="22494" xml_f="22591" txt_i="15881" txt_f="15978"> demonstrates a statistically significant difference in response rate. Perhaps the ongoing phase </offsets><sc><offsets xml_i="22595" xml_f="22597" txt_i="15978" txt_f="15980">ii</offsets></sc><offsets xml_i="22602" xml_f="22690" txt_i="15980" txt_f="16068"> trial (Southwest Oncology Group S0508) comparing thalidomide and temozolomide in stage </offsets><sc><offsets xml_i="22694" xml_f="22696" txt_i="16068" txt_f="16070">iv</offsets></sc><offsets xml_i="22701" xml_f="22913" txt_i="16070" txt_f="16282"> malignant melanoma will provide favourable results for this combination treatment. When larger confirmatory trials become available, the guideline will be updated and the recommendations revisited. The Melanoma </offsets><sc><offsets xml_i="22917" xml_f="22920" txt_i="16282" txt_f="16285">dsg</offsets></sc><offsets xml_i="22925" xml_f="23046" txt_i="16285" txt_f="16406"> previously submitted this practice guideline report to the Drug Quality and Therapeutics Committee/Cancer Care Ontario (</offsets><sc><offsets xml_i="23050" xml_f="23054" txt_i="16406" txt_f="16410">dqtc</offsets></sc><offsets xml_i="23059" xml_f="23060" txt_i="16410" txt_f="16411">/</offsets><sc><offsets xml_i="23064" xml_f="23067" txt_i="16411" txt_f="16414">cco</offsets></sc><offsets xml_i="23072" xml_f="23108" txt_i="16414" txt_f="16450">) in 2005 for funding consideration.</offsets></p></list-item></list></sec></sec><sec><title><offsets xml_i="23155" xml_f="23179" txt_i="16453" txt_f="16477">7. REPORT APPROVAL PANEL</offsets></title><sec sec-type="results"><title><offsets xml_i="23218" xml_f="23229" txt_i="16478" txt_f="16489">7.1 Results</offsets></title><p><offsets xml_i="23240" xml_f="23351" txt_i="16490" txt_f="16601">After the practitioner feedback survey had been addressed, the practice guideline report was circulated to the </offsets><sc><offsets xml_i="23355" xml_f="23359" txt_i="16601" txt_f="16605">pebc</offsets></sc><offsets xml_i="23364" xml_f="23618" txt_i="16605" txt_f="16859"> Report Approval Panel for further review. The Panel consists of two members, including an oncologist with expertise in clinical and methodology issues. The final report was reviewed and approved by the Panel in March 2006 on condition that the Melanoma </offsets><sc><offsets xml_i="23622" xml_f="23625" txt_i="16859" txt_f="16862">dsg</offsets></sc><offsets xml_i="23630" xml_f="23654" txt_i="16862" txt_f="16886"> address these concerns:</offsets></p><list list-type="bullet"><list-item><p><offsets xml_i="23697" xml_f="23826" txt_i="16887" txt_f="17016">The justification for recommending temozolomide appears to be based on the fact that it meets the “benchmark” set by dacarbazine.</offsets></p></list-item><list-item><p><offsets xml_i="23856" xml_f="23881" txt_i="17017" txt_f="17042">Given the existing phase </offsets><sc><offsets xml_i="23885" xml_f="23888" txt_i="17042" txt_f="17045">iii</offsets></sc><offsets xml_i="23893" xml_f="23904" txt_i="17045" txt_f="17056"> and phase </offsets><sc><offsets xml_i="23908" xml_f="23910" txt_i="17056" txt_f="17058">ii</offsets></sc><offsets xml_i="23915" xml_f="23997" txt_i="17058" txt_f="17140"> studies, the inclusion of single-arm trials has the potential to bias discussion.</offsets></p></list-item></list></sec><sec><title><offsets xml_i="24038" xml_f="24063" txt_i="17142" txt_f="17167">7.2 Modifications/Actions</offsets></title><p><offsets xml_i="24074" xml_f="24100" txt_i="17168" txt_f="17194">In response, the Melanoma </offsets><sc><offsets xml_i="24104" xml_f="24107" txt_i="17194" txt_f="17197">dsg</offsets></sc></p><list list-type="bullet"><list-item><p><offsets xml_i="24155" xml_f="24314" txt_i="17198" txt_f="17357">acknowledged the view that dacarbazine is widely regarded as the standard of care—albeit one with extremely limited efficacy in this disease. Furthermore, the </offsets><sc><offsets xml_i="24318" xml_f="24321" txt_i="17357" txt_f="17360">dsg</offsets></sc><offsets xml_i="24326" xml_f="24525" txt_i="17360" txt_f="17559"> members agree that temozolomide at least meets this standard and may be particularly applicable in the circumstances outlined in the report. Given that the “standard” leaves much to be desired, the </offsets><sc><offsets xml_i="24529" xml_f="24532" txt_i="17559" txt_f="17562">dsg</offsets></sc><offsets xml_i="24537" xml_f="24677" txt_i="17562" txt_f="17702"> recommends that untreated patients be strongly considered for clinical trials. A statement on dacarbazine has been added to the discussion.</offsets></p></list-item><list-item><p><offsets xml_i="24707" xml_f="24720" txt_i="17703" txt_f="17716">The Melanoma </offsets><sc><offsets xml_i="24724" xml_f="24727" txt_i="17716" txt_f="17719">dsg</offsets></sc><offsets xml_i="24732" xml_f="24846" txt_i="17719" txt_f="17833"> retained the single-arm trials because the limited evidence available made their inclusion appear necessary. The </offsets><sc><offsets xml_i="24850" xml_f="24853" txt_i="17833" txt_f="17836">dsg</offsets></sc><offsets xml_i="24858" xml_f="25050" txt_i="17836" txt_f="18028"> members realize that the results of these studies must be interpreted with caution because of their methodologic limitations, and they plan to refrain from including them in future documents.</offsets></p></list-item></list></sec></sec><sec><title><offsets xml_i="25097" xml_f="25118" txt_i="18031" txt_f="18052">8. PRACTICE GUIDELINE</offsets></title><p><offsets xml_i="25129" xml_f="25303" txt_i="18053" txt_f="18227">This practice guideline reflects the integration of the draft recommendations with feedback obtained during the external review process. It has been approved by the Melanoma </offsets><sc><offsets xml_i="25307" xml_f="25310" txt_i="18227" txt_f="18230">dsg</offsets></sc><offsets xml_i="25315" xml_f="25353" txt_i="18230" txt_f="18268"> and the Report Approval Panel of the </offsets><sc><offsets xml_i="25357" xml_f="25361" txt_i="18268" txt_f="18272">pbec</offsets></sc><offsets xml_i="25366" xml_f="25367" txt_i="18272" txt_f="18273">.</offsets></p><sec><title><offsets xml_i="25383" xml_f="25404" txt_i="18274" txt_f="18295">8.1 Target Population</offsets></title><p><offsets xml_i="25415" xml_f="25534" txt_i="18296" txt_f="18415">The recommendations in this practice guideline apply to adult patients with unresectable metastatic malignant melanoma.</offsets></p></sec><sec><title><offsets xml_i="25556" xml_f="25575" txt_i="18417" txt_f="18436">8.2 Recommendations</offsets></title><p><offsets xml_i="25586" xml_f="25655" txt_i="18437" txt_f="18506">Based on a systematic review of the available evidence, the Melanoma </offsets><sc><offsets xml_i="25659" xml_f="25662" txt_i="18506" txt_f="18509">dsg</offsets></sc><offsets xml_i="25667" xml_f="25741" txt_i="18509" txt_f="18583"> concludes that it is reasonable to use temozolomide at a dose of 200 mg/m</offsets><sup><offsets xml_i="25746" xml_f="25747" txt_i="18583" txt_f="18584">2</offsets></sup><offsets xml_i="25753" xml_f="25877" txt_i="18584" txt_f="18708"> orally for 5 days every 4 weeks as initial systemic treatment for patients with unresectable metastatic malignant melanoma.</offsets></p><p><offsets xml_i="25884" xml_f="25912" txt_i="18709" txt_f="18737">In a large randomized phase </offsets><sc><offsets xml_i="25916" xml_f="25919" txt_i="18737" txt_f="18740">iii</offsets></sc><offsets xml_i="25924" xml_f="25962" txt_i="18740" txt_f="18778"> study, the addition of moderate-dose </offsets><sc><offsets xml_i="25966" xml_f="25969" txt_i="18778" txt_f="18781">ifn</offsets></sc><offsets xml_i="25974" xml_f="26271" txt_i="18781" txt_f="19078"> has produced a significantly higher response rate than has single-agent temozolomide. However, overall survival was not altered and grades 3 and 4 hematologic toxicities were higher with the combined treatment. At the present time, the addition of interferon-α to temozolomide is not recommended.</offsets></p><p><offsets xml_i="26278" xml_f="26299" txt_i="19079" txt_f="19100">One randomized phase </offsets><sc><offsets xml_i="26303" xml_f="26305" txt_i="19100" txt_f="19102">ii</offsets></sc><offsets xml_i="26310" xml_f="26337" txt_i="19102" txt_f="19129"> study and six other phase </offsets><sc><offsets xml_i="26341" xml_f="26343" txt_i="19129" txt_f="19131">ii</offsets></sc><offsets xml_i="26348" xml_f="26783" txt_i="19131" txt_f="19566"> studies showed encouraging response rates when thalidomide was combined with temozolomide. However, the doses and schedules of temozolomide in those studies differed from the conventionally prescribed doses and schedules. It is not clear whether the improved response rates were attributable to the small number of patients in the studies, the different temozolomide doses and schedules, or the addition of thalidomide. Further phase </offsets><sc><offsets xml_i="26787" xml_f="26790" txt_i="19566" txt_f="19569">iii</offsets></sc><offsets xml_i="26795" xml_f="27008" txt_i="19569" txt_f="19782"> studies are required to confirm whether a benefit is associated with the combination of temozolomide and thalidomide. Therefore, at this time, it is not recommended that thalidomide be combined with temozolomide.</offsets></p></sec><sec><title><offsets xml_i="27030" xml_f="27055" txt_i="19784" txt_f="19809">8.3 Qualifying Statements</offsets></title><p><offsets xml_i="27066" xml_f="27609" txt_i="19810" txt_f="20353">Dacarbazine is the only chemotherapy drug currently approved for the treatment of patients with metastatic malignant melanoma. In large randomized trials, response rates with dacarbazine ranged from 6% to 15%. Almost all responses were partial, with a median response duration of only 7–8 months. Given these disappointing overall results, the consensus among most physicians who are treating patients with metastatic malignant melanoma is that recommending more convenient treatment or experimental treatment to these patients is appropriate.</offsets></p><p><offsets xml_i="27616" xml_f="27787" txt_i="20354" txt_f="20525">Because of oral dosing, temozolomide is a reasonable choice, particularly for patients who would have difficulty travelling to cancer centres for intravenous chemotherapy.</offsets></p><p><offsets xml_i="27794" xml_f="27884" txt_i="20526" txt_f="20616">Temozolomide has demonstrated efficacy equal to that of dacarbazine in a randomized phase </offsets><sc><offsets xml_i="27888" xml_f="27891" txt_i="20616" txt_f="20619">iii</offsets></sc><offsets xml_i="27896" xml_f="28292" txt_i="20619" txt_f="21015"> trial. However, unlike dacarbazine, temozolomide is a convenient oral treatment that penetrates the blood–brain barrier and that has shown activity against brain metastases. Although surgery is the preferred treatment modality for patients with solitary brain metastases from melanoma, temozolomide is the preferred chemotherapy for patients with brain metastases who require systemic treatment.</offsets></p></sec></sec><sec><title><offsets xml_i="28320" xml_f="28346" txt_i="21018" txt_f="21044">9. PRACTICE GUIDELINE DATE</offsets></title><p><offsets xml_i="28357" xml_f="28416" txt_i="21045" txt_f="21104">Completed March 2006. Practice guidelines developed by the </offsets><sc><offsets xml_i="28420" xml_f="28424" txt_i="21104" txt_f="21108">pbec</offsets></sc><offsets xml_i="28429" xml_f="28483" txt_i="21108" txt_f="21162"> are reviewed and updated regularly. Please visit the </offsets><sc><offsets xml_i="28487" xml_f="28491" txt_i="21162" txt_f="21166">pebc</offsets></sc><offsets xml_i="28496" xml_f="28509" txt_i="21166" txt_f="21179">’s Web site (</offsets><ext-link ext-link-type="uri" xlink:href="www.cancercare.on.ca/access_PEBC.htm"><offsets xml_i="28589" xml_f="28625" txt_i="21179" txt_f="21215">www.cancercare.on.ca/access_PEBC.htm</offsets></ext-link><offsets xml_i="28636" xml_f="28691" txt_i="21215" txt_f="21270">) for the full guideline report and subsequent updates.</offsets></p></sec></body><back><sec sec-type="display-objects"><title>Figures and Tables</title><table-wrap id="tI-co14_1p027" position="float"><label>TABLE I</label><caption><p>Practitioner responses to eight items on the practitioner feedback survey</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"></th><th colspan="3" align="center" rowspan="1"><italic>Respondents who [</italic>n <italic>(%)]</italic></th></tr><tr><th align="left" rowspan="1" colspan="1"><italic>Item</italic></th><th align="center" rowspan="1" colspan="1"><italic>Strongly agree or agree</italic></th><th align="center" rowspan="1" colspan="1"><italic>Neither agree nor disagree</italic></th><th align="center" rowspan="1" colspan="1"><italic>Strongly disagree or disagree</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">The rationale for developing a clinical practice guideline, as stated in the “Choice of Topic” section of the report, is clear.</td><td align="center" rowspan="1" colspan="1">6 (100)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">There is a need for a clinical practice guideline on this topic.</td><td align="center" rowspan="1" colspan="1">6 (100)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">The literature search is relevant and complete.</td><td align="center" rowspan="1" colspan="1">6 (100)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">The results of the trials described in the report are interpreted according to my understanding of the data.</td><td align="center" rowspan="1" colspan="1">6 (100)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">The draft recommendations in this report are clear.</td><td align="center" rowspan="1" colspan="1">6 (100)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">I agree with the draft recommendations as stated.</td><td align="center" rowspan="1" colspan="1">6 (100)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">This report should be approved as a practice guideline.</td><td align="center" rowspan="1" colspan="1">5 (83)</td><td align="center" rowspan="1" colspan="1">1 (17)</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td colspan="4" align="left" rowspan="1"><hr></hr></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"><italic>Very likely or likely</italic></td><td align="center" rowspan="1" colspan="1"><italic>Unsure</italic></td><td align="center" rowspan="1" colspan="1"><italic>Not at all likely or unlikely</italic></td></tr><tr><td colspan="4" align="left" rowspan="1"><hr></hr></td></tr><tr><td align="left" rowspan="1" colspan="1">If this report were to become a practice guideline, how likely would you be to make use of it in your own practice?</td><td align="center" rowspan="1" colspan="1">4 (67)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2 (33)</td></tr></tbody></table></table-wrap></sec><ref-list><title>10. REFERENCES</title><ref id="b1-co14_1p027"><label>1</label><citation citation-type="other">Canadian Cancer Society and the National Cancer Institute of Canada. <italic>Canadian Cancer Statistics 2005.</italic> Toronto: Canadian Cancer Society; 2005.</citation></ref><ref id="b2-co14_1p027"><label>2</label><citation citation-type="journal"><person-group><name><surname>Browman</surname><given-names>GP</given-names></name><name><surname>Levine</surname><given-names>MN</given-names></name><name><surname>Mohide</surname><given-names>EA</given-names></name><etal></etal></person-group><article-title>The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation</article-title><source>J Clin Oncol</source><year>1995</year><volume>13</volume><fpage>502</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">7844612</pub-id></citation></ref><ref id="b3-co14_1p027"><label>3</label><citation citation-type="journal"><person-group><name><surname>Middleton</surname><given-names>MR</given-names></name><name><surname>Grob</surname><given-names>JJ</given-names></name><name><surname>Aaronson</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Randomized phase iii study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>158</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">10623706</pub-id></citation></ref><ref id="b4-co14_1p027"><label>4</label><citation citation-type="journal"><person-group><name><surname>Kaufmann</surname><given-names>R</given-names></name><name><surname>Spieth</surname><given-names>K</given-names></name><name><surname>Lejeune</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase iii, multicenter study from the Dermatologic Cooperative Oncology Group</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15545667</pub-id></citation></ref><ref id="b5-co14_1p027"><label>5</label><citation citation-type="journal"><person-group><name><surname>Bafaloukos</surname><given-names>D</given-names></name><name><surname>Tsoutsos</surname><given-names>D</given-names></name><name><surname>Kalofonos</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Temozolomide and cisplatin vs temozolomide in patients with advanced melanoma: a randomized phase ii study of the Hellenic Cooperative Oncology Group</article-title><source>Ann Oncol</source><year>2005</year><volume>16</volume><fpage>950</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15829494</pub-id></citation></ref><ref id="b6-co14_1p027"><label>6</label><citation citation-type="journal"><person-group><name><surname>Danson</surname><given-names>S</given-names></name><name><surname>Lorigan</surname><given-names>P</given-names></name><name><surname>Arance</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Randomized phase ii study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>2551</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12829675</pub-id></citation></ref><ref id="b7-co14_1p027"><label>7</label><citation citation-type="journal"><person-group><name><surname>Richtig</surname><given-names>E</given-names></name><name><surname>Hofmann–Wellenhof</surname><given-names>R</given-names></name><name><surname>Pehamberger</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Temozolomide and interferon a2b in metastatic melanoma stage iv</article-title><source>Br J Dermatol</source><year>2004</year><volume>151</volume><fpage>91</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15270876</pub-id></citation></ref><ref id="b8-co14_1p027"><label>8</label><citation citation-type="journal"><person-group><name><surname>Agarwala</surname><given-names>SS</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name><name><surname>Gore</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Temozolomide for the treatment of brain metastases associated with meta-static melanoma: a phase ii study</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>2101</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15169796</pub-id></citation></ref><ref id="b9-co14_1p027"><label>9</label><citation citation-type="journal"><person-group><name><surname>Serrone</surname><given-names>L</given-names></name><name><surname>Freschi</surname><given-names>A</given-names></name><name><surname>Chiarion–Sileni</surname><given-names>V</given-names></name><etal></etal></person-group><article-title>Radiotherapy followed by temozolomide in the treatment of patients with melanoma metastatic to the brain: an Italian multicentre study [abstract 7558]</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><issue>suppl 14</issue><fpage>724s</fpage></citation></ref><ref id="b10-co14_1p027"><label>10</label><citation citation-type="journal"><person-group><name><surname>Bedikian</surname><given-names>AY</given-names></name><name><surname>Papadopoulos</surname><given-names>N</given-names></name><name><surname>Plager</surname><given-names>C</given-names></name><name><surname>Eton</surname><given-names>O</given-names></name><name><surname>Ring</surname><given-names>S</given-names></name></person-group><article-title>Phase ii evaluation of temozolomide in metastatic choroidal melanoma</article-title><source>Melanoma Res</source><year>2003</year><volume>13</volume><fpage>303</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12777987</pub-id></citation></ref><ref id="b11-co14_1p027"><label>11</label><citation citation-type="journal"><person-group><name><surname>Berrocal</surname><given-names>A</given-names></name><name><surname>Blasco</surname><given-names>A</given-names></name><name><surname>Camps</surname><given-names>C</given-names></name><name><surname>Caballero</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Gonzalez</surname><given-names>C</given-names></name></person-group><article-title>Phase ii trial of long term temozolomide administration in metastatic melanoma. Preliminary results [abstract 2892]</article-title><source>Proc Am Soc Clin Oncol</source><year>2003</year><volume>22</volume><fpage>719</fpage></citation></ref><ref id="b12-co14_1p027"><label>12</label><citation citation-type="journal"><person-group><name><surname>Middleton</surname><given-names>MR</given-names></name><name><surname>Lee</surname><given-names>SM</given-names></name><name><surname>Arance</surname><given-names>A</given-names></name><name><surname>Wood</surname><given-names>M</given-names></name><name><surname>Thatcher</surname><given-names>N</given-names></name><name><surname>Margison</surname><given-names>GP</given-names></name></person-group><article-title>O<sub>6</sub>-Methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase ii study</article-title><source>Int J Cancer</source><year>2000</year><volume>88</volume><fpage>469</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">11054678</pub-id></citation></ref><ref id="b13-co14_1p027"><label>13</label><citation citation-type="journal"><person-group><name><surname>Middleton</surname><given-names>MR</given-names></name><name><surname>Lunn</surname><given-names>JM</given-names></name><name><surname>Morris</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>O<sub>6</sub>-Methylguanine–dna methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma</article-title><source>Br J Cancer</source><year>1998</year><volume>78</volume><fpage>1199</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">9820180</pub-id></citation></ref><ref id="b14-co14_1p027"><label>14</label><citation citation-type="journal"><person-group><name><surname>Lunn</surname><given-names>JM</given-names></name><name><surname>Wedge</surname><given-names>SR</given-names></name><name><surname>Rustin</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Measurement of pre-methyltransferase treatment levels of O<sub>6</sub>-methylguanine–DNA (mgmt) in tumor biopsies as an indication of the clinical response of malignant melanoma to temozolomide [abstract 2617]</article-title><source>Proc Am Assoc Cancer Res</source><year>1997</year><volume>38</volume><fpage>390</fpage></citation></ref><ref id="b15-co14_1p027"><label>15</label><citation citation-type="journal"><person-group><name><surname>Bleehen</surname><given-names>NM</given-names></name><name><surname>Newlands</surname><given-names>ES</given-names></name><name><surname>Lee</surname><given-names>SM</given-names></name><etal></etal></person-group><article-title>Cancer Research Campaign phase ii trial of temozolomide in metastatic melanoma</article-title><source>J Clin Oncol</source><year>1995</year><volume>13</volume><fpage>910</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">7707118</pub-id></citation></ref><ref id="b16-co14_1p027"><label>16</label><citation citation-type="journal"><person-group><name><surname>Newlands</surname><given-names>ES</given-names></name><name><surname>Blackledge</surname><given-names>GR</given-names></name><name><surname>Slack</surname><given-names>JA</given-names></name><etal></etal></person-group><article-title>Phase i trial of temozolomide (CCRG 81045: M&amp;B 39831: NSC 362856)</article-title><source>Br J Cancer</source><year>1992</year><volume>65</volume><fpage>287</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">1739631</pub-id></citation></ref><ref id="b17-co14_1p027"><label>17</label><citation citation-type="journal"><person-group><name><surname>Dereure</surname><given-names>O</given-names></name><name><surname>Khamari</surname><given-names>A</given-names></name><name><surname>Cupissol</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Multicenter phase i/ii study evaluating maximal tolerated dosage and clinical efficacy of an association of temozolomide with Peg-Intron in patients with metastatic melanoma [abstract 7548]</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><issue>suppl 14</issue><fpage>722s</fpage></citation></ref><ref id="b18-co14_1p027"><label>18</label><citation citation-type="journal"><person-group><name><surname>Krown</surname><given-names>SE</given-names></name><name><surname>Hwu</surname><given-names>WJ</given-names></name><name><surname>Menell</surname><given-names>JH</given-names></name><etal></etal></person-group><article-title>A phase ii study of temozolomide (tmz) and pegylated interferon alpha-2b (pgi) in the treatment of advanced melanoma [abstract 7533]</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><issue>suppl 14</issue><fpage>718s</fpage></citation></ref><ref id="b19-co14_1p027"><label>19</label><citation citation-type="journal"><person-group><name><surname>Ridolfi</surname><given-names>R</given-names></name><name><surname>Romanini</surname><given-names>A</given-names></name><name><surname>Chiarion Sileni</surname><given-names>V</given-names></name><etal></etal></person-group><article-title>Temozolomide and interferon-alpha in metastatic melanoma: a phase ii study of the Italian Melanoma Intergroup</article-title><source>Melanoma Res</source><year>2004</year><volume>14</volume><fpage>295</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15305161</pub-id></citation></ref><ref id="b20-co14_1p027"><label>20</label><citation citation-type="journal"><person-group><name><surname>Agarwala</surname><given-names>SS</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name></person-group><article-title>Temozolomide in combination with interferon α-2b in patients with metastatic melanoma. A phase i dose-escalation study</article-title><source>Cancer</source><year>2003</year><volume>97</volume><fpage>121</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12491513</pub-id></citation></ref><ref id="b21-co14_1p027"><label>21</label><citation citation-type="journal"><person-group><name><surname>Delva</surname><given-names>R</given-names></name><name><surname>Lesimple</surname><given-names>T</given-names></name><name><surname>Delcambre</surname><given-names>C</given-names></name><name><surname>Sassolas</surname><given-names>B</given-names></name><name><surname>Plantin</surname><given-names>P</given-names></name><name><surname>Bugnot</surname><given-names>C</given-names></name></person-group><article-title>A phase ii study of sub-cutaneous (sc) interferon alpha (ifn) and oral temozolomide (tmz) combination after chemo-sensibilisation by high doses intravenous (iv) ifn as first-line treatment in patients with metastatic malignant melanoma [abstract 2886]</article-title><source>Proc Am Soc Clin Oncol</source><year>2003</year><volume>22</volume><fpage>718</fpage></citation></ref><ref id="b22-co14_1p027"><label>22</label><citation citation-type="journal"><person-group><name><surname>Garcia Martin</surname><given-names>M</given-names></name><name><surname>Tres</surname><given-names>A</given-names></name><name><surname>Crespo</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Phase ii multicenter study of temozolomide in combination with interferon alfa-2b in metastatic malignant melanoma [abstract 1389]</article-title><source>Proc Am Soc Clin Oncol</source><year>2002</year><volume>21</volume><fpage>348</fpage></citation></ref><ref id="b23-co14_1p027"><label>23</label><citation citation-type="journal"><person-group><name><surname>Okeke</surname><given-names>I</given-names></name><name><surname>Laber</surname><given-names>D</given-names></name><name><surname>Bev</surname><given-names>T</given-names></name><name><surname>McMasters</surname><given-names>K</given-names></name><name><surname>Miller</surname><given-names>D</given-names></name></person-group><article-title>Temozolomide and thalidomide in the treatment of advanced melanoma, a phase ii study [abstract 7573]</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>728s</fpage></citation></ref><ref id="b24-co14_1p027"><label>24</label><citation citation-type="journal"><person-group><name><surname>Hwu</surname><given-names>WJ</given-names></name><name><surname>Lis</surname><given-names>E</given-names></name><name><surname>Manell</surname><given-names>JH</given-names></name><name><surname>Panageas</surname><given-names>KS</given-names></name><name><surname>Lamb</surname><given-names>LA</given-names></name><name><surname>Merrell</surname><given-names>J</given-names></name></person-group><article-title>Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase ii study</article-title><source>Cancer</source><year>2005</year><volume>103</volume><fpage>2590</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15861414</pub-id></citation></ref><ref id="b25-co14_1p027"><label>25</label><citation citation-type="journal"><person-group><name><surname>Atkins</surname><given-names>MB</given-names></name><name><surname>Sosman</surname><given-names>J</given-names></name><name><surname>Agarwala</surname><given-names>S</given-names></name><name><surname>Logan</surname><given-names>T</given-names></name><name><surname>Clark</surname><given-names>J</given-names></name><name><surname>Ernstoff</surname><given-names>M</given-names></name></person-group><article-title>A Cytokine Working Group phase ii study of temozolomide (tmz), thalidomide (thal) and whole brain radiation therapy (wbrt) for patients with brain metastases from melanoma [abstract 7552]</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>723s</fpage></citation></ref><ref id="b26-co14_1p027"><label>26</label><citation citation-type="journal"><person-group><name><surname>Hwu</surname><given-names>WJ</given-names></name><name><surname>Krown</surname><given-names>SE</given-names></name><name><surname>Menell</surname><given-names>JH</given-names></name><etal></etal></person-group><article-title>Phase ii study of temozolomide plus thalidomide for the treatment of metastatic melanoma</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>3351</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12947072</pub-id></citation></ref><ref id="b27-co14_1p027"><label>27</label><citation citation-type="journal"><person-group><name><surname>Mehta</surname><given-names>AC</given-names></name><name><surname>Laber</surname><given-names>DA</given-names></name><name><surname>McMasters</surname><given-names>KM</given-names></name><name><surname>Taft</surname><given-names>B</given-names></name><name><surname>Coons</surname><given-names>K</given-names></name><name><surname>Miller</surname><given-names>DM</given-names></name></person-group><article-title>A phase ii study of temozolomide and thalidomide in the treatment of advanced melanoma [abstract 2907]</article-title><source>Proc Am Soc Clin Oncol</source><year>2003</year><volume>22</volume><fpage>723</fpage></citation></ref><ref id="b28-co14_1p027"><label>28</label><citation citation-type="journal"><person-group><name><surname>Hwu</surname><given-names>WJ</given-names></name><name><surname>Krown</surname><given-names>SE</given-names></name><name><surname>Panageas</surname><given-names>KS</given-names></name><etal></etal></person-group><article-title>Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>2610</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">12039921</pub-id></citation></ref></ref-list><fn-group><fn id="fn1-co14_p027"><p>The Cancer Care Ontario Practice Guidelines Initiative is sponsored by Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care</p></fn></fn-group></back></article>